{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T07:24:15Z","timestamp":1778052255641,"version":"3.51.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s11523-026-01200-9","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T15:12:48Z","timestamp":1772205168000},"page":"237-253","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prognostic Impact of Metastatic Sites in Patients with Biliary Tract Cancer Treated with Cisplatin, Gemcitabine, and Durvalumab"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8203-1684","authenticated-orcid":false,"given":"Silvia","family":"Camera","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Fornaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margherita","family":"Rimini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mara","family":"Persano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario Domenico","family":"Rizzato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Saborowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Antonuzzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Rossari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyuki","family":"Satake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederik","family":"Peeters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Salani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Bozzarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Corallo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Lucchetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oluseyi","family":"Abidoye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilario Giovanni","family":"Rapposelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Gallio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Tamberi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabian","family":"Finkelmeier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pircher","family":"Chiara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong Jae","family":"Chon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Braconi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aitzaz","family":"Qaisar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Pastorino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Castet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emiliano","family":"Tamburini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changhoon","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Parisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Diana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Scartozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald W.","family":"Prager","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Avallone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Schirripa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Il Hwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukas","family":"Perkhofer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ester","family":"Oneda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Verrico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuno","family":"Couto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Adeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen L.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gian Paolo","family":"Spinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Personeni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid","family":"Garajova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Grazia","family":"Rodriquenz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvana","family":"Leo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilia","family":"Melo Alvim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"Roque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Farinea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Genovesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"De Rosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Lavacchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Lo Prinzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Passeri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Ferrara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Foti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeroen","family":"Dekervel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Niger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Balsano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Tonini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minsu","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Tesini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Casadio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vera","family":"Himmelsbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Landriscina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selma","family":"Ahcene Djaballah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanios","family":"Bekaii-Saab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluca","family":"Masi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arndt","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Lonardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caterina","family":"Vivaldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenza","family":"Rimassa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Casadei-Gardini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"issue":"2","key":"1200_CR1","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","volume":"34","author":"A Vogel","year":"2023","unstructured":"Vogel A, Bridgewater J, Edeline J, Kelley RK, Kl\u00fcmpen HJ, Malka D, et al. Biliary tract cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(2):127\u201340. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.506.","journal-title":"Ann Oncol"},{"issue":"1","key":"1200_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.104003","volume":"10","author":"A Vogel","year":"2025","unstructured":"Vogel A, Ducreux M, ESMO Guidelines Committee. ESMO clinical practice guideline interim update on the management of biliary tract cancer. ESMO Open. 2025;10(1):104003. https:\/\/doi.org\/10.1016\/j.esmoop.2024.104003.","journal-title":"ESMO Open"},{"issue":"5","key":"1200_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2022.100737","volume":"27","author":"A Elvevi","year":"2022","unstructured":"Elvevi A, Laffusa A, Scaravaglio M, Rossi RE, Longarini R, Stagno AM, et al. Clinical treatment of cholangiocarcinoma: an updated comprehensive review. Ann Hepatol. 2022;27(5):100737. https:\/\/doi.org\/10.1016\/j.aohep.2022.100737.","journal-title":"Ann Hepatol"},{"issue":"1","key":"1200_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-10286-z","volume":"22","author":"J Koshiol","year":"2022","unstructured":"Koshiol J, Yu B, Kabadi SM, Baria K, Shroff RT. Epidemiologic patterns of biliary tract cancer in the United States: 2001\u20132015. BMC Cancer. 2022;22(1):1178. https:\/\/doi.org\/10.1186\/s12885-022-10286-z.","journal-title":"BMC Cancer"},{"issue":"4","key":"1200_CR5","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.gastha.2022.04.007","volume":"1","author":"K Baria","year":"2022","unstructured":"Baria K, De Toni EN, Yu B, Jiang Z, Kabadi SM, Malvezzi M. Worldwide incidence and mortality of biliary tract cancer. Gastro Hep Adv. 2022;1(4):618\u201326. https:\/\/doi.org\/10.1016\/j.gastha.2022.04.007.","journal-title":"Gastro Hep Adv"},{"issue":"8","key":"1200_CR6","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200015","volume":"1","author":"DY Oh","year":"2022","unstructured":"Oh DY, Ruth He A, Qin S, Chen LT, Okusaka T, Vogel A, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 2022;1(8):EVIDoa2200015. https:\/\/doi.org\/10.1056\/EVIDoa2200015.","journal-title":"NEJM Evid"},{"issue":"8","key":"1200_CR7","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","volume":"9","author":"DY Oh","year":"2024","unstructured":"Oh DY, He AR, Bouattour M, Okusaka T, Qin S, Chen LT, et al. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study. Lancet Gastroenterol Hepatol. 2024;9(8):694\u2013704. https:\/\/doi.org\/10.1016\/S2468-1253(24)00095-5.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10391","key":"1200_CR8","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401(10391):1853\u201365. https:\/\/doi.org\/10.1016\/S0140-6736(23)00727-4.","journal-title":"Lancet"},{"issue":"3","key":"1200_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101290","volume":"7","author":"Z Li","year":"2024","unstructured":"Li Z, Aliseda D, Jones O, Rajendran L, Magyar C, Grant R, et al. Recent advances in systemic therapy for advanced biliary tract cancer: a systematic review and meta-analysis using reconstructed RCT survival data. JHEP Rep. 2024;7(3):101290. https:\/\/doi.org\/10.1016\/j.jhepr.2024.101290.","journal-title":"JHEP Rep."},{"issue":"8","key":"1200_CR10","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1111\/liv.15641","volume":"43","author":"M Rimini","year":"2023","unstructured":"Rimini M, Fornaro L, Lonardi S, Niger M, Lavacchi D, Pressiani T, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: an early exploratory analysis of real-world data. Liver Int. 2023;43(8):1803\u201312. https:\/\/doi.org\/10.1111\/liv.15641.","journal-title":"Liver Int"},{"key":"1200_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114199","volume":"208","author":"M Rimini","year":"2024","unstructured":"Rimini M, Fornaro L, Rizzato MD, Antonuzzo L, Rossari F, Satake T, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: a large real-life worldwide population. Eur J Cancer. 2024;208:114199. https:\/\/doi.org\/10.1016\/j.ejca.2024.114199.","journal-title":"Eur J Cancer"},{"issue":"9","key":"1200_CR12","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1002\/ueg2.12656","volume":"12","author":"K Mitzlaff","year":"2024","unstructured":"Mitzlaff K, Kirstein MM, M\u00fcller C, Venerito M, Olkus A, Dill MT, et al. Efficacy, safety and differential outcomes of immune-chemotherapy with gemcitabine, cisplatin and durvalumab in patients with biliary tract cancers: a multicenter real world cohort. United Eur Gastroenterol J. 2024;12(9):1230\u201342. https:\/\/doi.org\/10.1002\/ueg2.12656.","journal-title":"United Eur Gastroenterol J"},{"key":"1200_CR13","doi-asserted-by":"publisher","DOI":"10.1200\/GO.24.00216","volume":"10","author":"VK Muddu","year":"2024","unstructured":"Muddu VK, Shah A, John A, Raj A, Bahl A, Rajappa SJ, et al. Gemcitabine cisplatin and durvalumab experience in advanced biliary tract cancers: a real-world, multicentric data from India. JCO Glob Oncol. 2024;10:e2400216. https:\/\/doi.org\/10.1200\/GO.24.00216.","journal-title":"JCO Glob Oncol."},{"issue":"2","key":"1200_CR14","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s11523-024-01044-1","volume":"19","author":"A Olkus","year":"2024","unstructured":"Olkus A, Tomczak A, Berger AK, Rauber C, Puchas P, Wehling C, et al. Durvalumab plus gemcitabine and cisplatin in patients with advanced biliary tract cancer: an exploratory analysis of real-world data. Target Oncol. 2024;19(2):213\u201321. https:\/\/doi.org\/10.1007\/s11523-024-01044-1.","journal-title":"Target Oncol"},{"issue":"6","key":"1200_CR15","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1002\/hep.31598","volume":"73","author":"A Lamarca","year":"2021","unstructured":"Lamarca A, Santos-Laso A, Utpatel K, La Casta A, Stock S, Forner A, et al. Liver metastases of intrahepatic cholangiocarcinoma: implications for an updated staging system. Hepatology. 2021;73(6):2311\u201325. https:\/\/doi.org\/10.1002\/hep.31598.","journal-title":"Hepatology"},{"issue":"49","key":"1200_CR16","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000018191","volume":"98","author":"R Cheng","year":"2019","unstructured":"Cheng R, Du Q, Ye J, Wang B, Chen Y. Prognostic value of site-specific metastases for patients with advanced intrahepatic cholangiocarcinoma: a SEER database analysis. Medicine (Baltimore). 2019;98(49):e18191. https:\/\/doi.org\/10.1097\/MD.0000000000018191.","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"1200_CR17","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1093\/jnci\/djz071","volume":"112","author":"A Lamarca","year":"2020","unstructured":"Lamarca A, Ross P, Wasan HS, Hubner RA, McNamara MG, Lopes A, et al. Advanced intrahepatic cholangiocarcinoma: post hoc analysis of the ABC-01, -02, and -03 clinical trials. J Natl Cancer Inst. 2020;112(2):200\u201310. https:\/\/doi.org\/10.1093\/jnci\/djz071.","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"1200_CR18","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.3390\/curroncol30030199","volume":"30","author":"I Garajov\u00e1","year":"2023","unstructured":"Garajov\u00e1 I, Gelsomino F, Salati M, Leonardi F, De Lorenzo S, Granito A, et al. Bone metastases from intrahepatic cholangiocarcinoma confer worse prognosis. Curr Oncol. 2023;30(3):2613\u201324. https:\/\/doi.org\/10.3390\/curroncol30030199.","journal-title":"Curr Oncol"},{"key":"1200_CR19","doi-asserted-by":"publisher","first-page":"7195373","DOI":"10.1155\/2020\/7195373","volume":"2020","author":"F Hahn","year":"2020","unstructured":"Hahn F, M\u00fcller L, M\u00e4hringer-Kunz A, Tanyildizi Y, Dos Santos DP, D\u00fcber C, et al. Distant metastases in patients with intrahepatic cholangiocarcinoma: does location matter? A retrospective analysis of 370 patients. J Oncol. 2020;2020:7195373. https:\/\/doi.org\/10.1155\/2020\/7195373.","journal-title":"J Oncol"},{"issue":"16","key":"1200_CR20","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1056\/NEJMra030831","volume":"350","author":"GD Roodman","year":"2004","unstructured":"Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350(16):1655\u201364. https:\/\/doi.org\/10.1056\/NEJMra030831.","journal-title":"N Engl J Med"},{"issue":"8","key":"1200_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15082383","volume":"15","author":"MSC Ornella","year":"2023","unstructured":"Ornella MSC, Badrinath N, Kim KA, Kim JH, Cho E, Hwang TH, et al. Immunotherapy for peritoneal carcinomatosis: challenges and prospective outcomes. Cancers (Basel). 2023;15(8):2383. https:\/\/doi.org\/10.3390\/cancers15082383.","journal-title":"Cancers (Basel)"},{"issue":"7","key":"1200_CR22","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1080\/13543784.2021.1916912","volume":"30","author":"JJ Marin","year":"2021","unstructured":"Marin JJ, Macias RI. Understanding drug resistance mechanisms in cholangiocarcinoma: assisting the clinical development of investigational drugs. Expert Opin Investig Drugs. 2021;30(7):675\u20139. https:\/\/doi.org\/10.1080\/13543784.2021.1916912.","journal-title":"Expert Opin Investig Drugs"},{"issue":"3-4","key":"1200_CR23","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1053\/j.seminoncol.2024.04.001","volume":"51","author":"O Giulia","year":"2024","unstructured":"Giulia O, Alessandro B, Angelo C, Paolo M, Rosa C, Marina M, et al. Isolated lung metastases from pancreatic ductal adenocarcinoma (PDAC): diagnostic and therapeutic challenges of a different disease. Semin Oncol. 2024;51(3\u20134):69\u201376. https:\/\/doi.org\/10.1053\/j.seminoncol.2024.04.001.","journal-title":"Semin Oncol"},{"key":"1200_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.1579","volume":"35","author":"L Mercier","year":"2024","unstructured":"Mercier L, Boileve A, Ducreux MP, Lambert A, Tarabay A, Hollebecque A, et al. 1516P lung-only metastatic PDAC: another disease? Ann Oncol. 2024;35:S927. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.1579.","journal-title":"Ann Oncol"},{"issue":"5","key":"1200_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15051523","volume":"15","author":"L Ielasi","year":"2023","unstructured":"Ielasi L, Tovoli F, Tonnini M, Stefanini B, Tortora R, Magini G, et al. Prognostic impact of metastatic site in patients receiving first-line sorafenib therapy for advanced hepatocellular carcinoma. Cancers (Basel). 2023;15(5):1523. https:\/\/doi.org\/10.3390\/cancers15051523.","journal-title":"Cancers (Basel)"},{"issue":"18","key":"1200_CR26","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.2217\/fon-2018-0846","volume":"15","author":"X Yan","year":"2019","unstructured":"Yan X, Wang P, Zhu Z, Ning Z, Xu L, Zhuang L, et al. Site-specific metastases of intrahepatic cholangiocarcinoma and its impact on survival: a population-based study. Future Oncol. 2019;15(18):2125\u201337. https:\/\/doi.org\/10.2217\/fon-2018-0846.","journal-title":"Future Oncol"},{"issue":"7","key":"1200_CR27","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/s41571-023-00770-1","volume":"20","author":"SI Ilyas","year":"2023","unstructured":"Ilyas SI, Affo S, Goyal L, Lamarca A, Sapisochin G, Yang JD, et al. Cholangiocarcinoma - novel biological insights and therapeutic strategies. Nat Rev Clin Oncol. 2023;20(7):470\u201386. https:\/\/doi.org\/10.1038\/s41571-023-00770-1.","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"1200_CR28","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1002\/hep.31829","volume":"74","author":"T Boerner","year":"2021","unstructured":"Boerner T, Drill E, Pak LM, Nguyen B, Sigel CS, Doussot A, et al. Genetic determinants of outcome in intrahepatic cholangiocarcinoma. Hepatology. 2021;74(3):1429\u201344. https:\/\/doi.org\/10.1002\/hep.31829.","journal-title":"Hepatology"},{"issue":"6","key":"1200_CR29","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.21037\/jgo-21-776","volume":"12","author":"Y Zheng","year":"2021","unstructured":"Zheng Y, Qin Y, Gong W, Li H, Li B, Wang Y, et al. Specific genomic alterations and prognostic analysis of perihilar cholangiocarcinoma and distal cholangiocarcinoma. J Gastrointest Oncol. 2021;12(6):2631\u201342. https:\/\/doi.org\/10.21037\/jgo-21-776.","journal-title":"J Gastrointest Oncol"},{"key":"1200_CR30","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae256","author":"F Lo Prinzi","year":"2024","unstructured":"Lo Prinzi F, Salani F, Rimini M, Rizzato MD, Antonuzzo L, Camera S, et al. Efficacy of cisplatin\u2013gemcitabine\u2013durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population. Oncologist. 2024. https:\/\/doi.org\/10.1093\/oncolo\/oyae256.","journal-title":"Oncologist"},{"key":"1200_CR31","unstructured":"Rimini M, Brandi G, Leone F, Fornaro L, Burgio V, Casagrande M, et al. Impact of previous surgery on prognosis in patients with cholangiocarcinoma under chemotherapy. ILCA Annual Conference 2021, 2021, digital platform. Poster."},{"issue":"9","key":"1200_CR32","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/j.ejca.2014.02.015","volume":"50","author":"MG McNamara","year":"2014","unstructured":"McNamara MG, Templeton AJ, Maganti M, Walter T, Horgan AM, McKeever L, et al. Neutrophil\/lymphocyte ratio as a prognostic factor in biliary tract cancer. Eur J Cancer. 2014;50(9):1581\u20139.","journal-title":"Eur J Cancer"},{"issue":"5","key":"1200_CR33","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.jhep.2021.12.010","volume":"76","author":"L Izquierdo-Sanchez","year":"2022","unstructured":"Izquierdo-Sanchez L, Lamarca A, La Casta A, Buettner S, Utpatel K, Kl\u00fcmpen HJ, et al. Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA Registry. J Hepatol. 2022;76(5):1109\u201321. https:\/\/doi.org\/10.1016\/j.jhep.2021.12.010.","journal-title":"J Hepatol"},{"issue":"6","key":"1200_CR34","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3978\/j.issn.2078-6891.2014.081","volume":"5","author":"RD Peixoto","year":"2014","unstructured":"Peixoto RD, Renouf D, Lim H. A population based analysis of prognostic factors in advanced biliary tract cancer. J Gastrointest Oncol. 2014;5(6):428\u201332. https:\/\/doi.org\/10.3978\/j.issn.2078-6891.2014.081.","journal-title":"J Gastrointest Oncol"},{"issue":"8","key":"1200_CR35","doi-asserted-by":"publisher","first-page":"5085","DOI":"10.1007\/s00432-022-04424-0","volume":"149","author":"M Ma\u00dfmann","year":"2023","unstructured":"Ma\u00dfmann M, Treckmann J, Markus P, Schumacher B, Albers D, Ting S, et al. A prognostic systemic inflammation score (SIS) in patients with advanced intrahepatic cholangiocarcinoma. J Cancer Res Clin Oncol. 2023;149(8):5085\u201394. https:\/\/doi.org\/10.1007\/s00432-022-04424-0.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"1200_CR36","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00262-015-1780-7","volume":"65","author":"BS Lee","year":"2016","unstructured":"Lee BS, Lee SH, Son JH, Jang DK, Chung KH, Lee YS, et al. Neutrophil\u2013lymphocyte ratio predicts survival in patients with advanced cholangiocarcinoma on chemotherapy. Cancer Immunol Immunother. 2016;65(2):141\u201350. https:\/\/doi.org\/10.1007\/s00262-015-1780-7.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"1200_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17175-7","volume":"7","author":"SH Loosen","year":"2017","unstructured":"Loosen SH, Roderburg C, Kauertz KL, Koch A, Vucur M, Schneider AT, et al. CEA but not CA19-9 is an independent prognostic factor in patients undergoing resection of cholangiocarcinoma. Sci Rep. 2017;7(1):16975. https:\/\/doi.org\/10.1038\/s41598-017-17175-7.","journal-title":"Sci Rep"},{"issue":"1","key":"1200_CR38","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1093\/annonc\/mdv483","volume":"27","author":"J Bridgewater","year":"2016","unstructured":"Bridgewater J, Lopes A, Wasan H, Malka D, Jensen L, Okusaka T, et al. Prognostic factors for progression-free and overall survival in advanced biliary tract cancer. Ann Oncol. 2016;27(1):134\u201340. https:\/\/doi.org\/10.1093\/annonc\/mdv483.","journal-title":"Ann Oncol"},{"issue":"6","key":"1200_CR39","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1111\/liv.14813","volume":"41","author":"EJ Kim","year":"2021","unstructured":"Kim EJ, Yoo C, Kang HJ, Kim KP, Ryu MH, Park SR, et al. Clinical outcomes of systemic therapy in patients with unresectable or metastatic combined hepatocellular-cholangiocarcinoma. Liver Int. 2021;41(6):1398\u2013408. https:\/\/doi.org\/10.1111\/liv.14813.","journal-title":"Liver Int"},{"key":"1200_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114196","volume":"207","author":"T Pressiani","year":"2024","unstructured":"Pressiani T, Balsano R, Giordano L, Milella M, Bergamo F, Bozzarelli S, et al. Multicenter phase I\/II trial of gemcitabine, oxaliplatin and nab-paclitaxel as first-line treatment for patients with advanced biliary tract cancer. Eur J Cancer. 2024;207:114196. https:\/\/doi.org\/10.1016\/j.ejca.2024.114196.","journal-title":"Eur J Cancer"},{"key":"1200_CR41","doi-asserted-by":"crossref","unstructured":"Lamarca A. Advanced extrahepatic cholangiocarcinoma: Post-hoc analysis of the ABC-01, -02 and -03 clinical trials. Mini oral session 1 - Gastrointestinal tumours, upper digestive. Presented at: European Society for Medical Oncology (ESMO) Congress 2023; 2023 Oct 20\u201324; Madrid, Spain.","DOI":"10.1016\/j.annonc.2023.09.1387"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01200-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-026-01200-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01200-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T16:57:59Z","timestamp":1774630679000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-026-01200-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1200"],"URL":"https:\/\/doi.org\/10.1007\/s11523-026-01200-9","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"assertion":[{"value":"18 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Lorenza Rimassa received consulting fees from AbbVie, AstraZeneca, Basilea, Bayer, BMS, Eisai, Elevar Therapeutics, Exelixis, Genenta, Hengrui, Incyte, Ipsen, Jazz Pharmaceuticals, MSD, Nerviano Medical Sciences, Roche, Servier, Taiho Oncology, and Zymeworks; lecture fees from AstraZeneca, Bayer, BMS, Guerbet, Incyte, Ipsen, and Roche, Servier; travel expenses from AstraZeneca and Servier; and research grants (to institution) from AbbVie, AstraZeneca, BeiGene, Exelixis, Fibrogen, Incyte, Ipsen, Jazz Pharmaceuticals, MSD, Nerviano Medical Sciences, Roche, Servier, Taiho Oncology, TransThera Sciences, and Zymeworks. Andrea Casadei-Gardini reports consulting fees from AstraZeneca, Bayer, BMS, Eisai, Incyte, Ipsen, IQVIA, MSD, Roche, and Servier; lecture fees from AstraZeneca, Bayer, BMS, Eisai, Incyte, Ipsen, Roche, and Servier; travel expenses from AstraZeneca; and research grants (to institution) from AstraZeneca and Eisai. Lorenzo Fornaro: speaking honoraria: Incyte, Bristol Myers Squibb, and MSD; advisory board\/consultant: MSD, AstraZeneca, Incyte, Taiho, Servier, Daiichi Sankyo, and Astellas; institutional research funding: MSD, Bristol Myers Squibb, AstraZeneca, Incyte, BeiGene, Astellas, Daiichi Sankyo, and Roche. Stephen L. Chan serves as an advisory member for AstraZeneca, MSD, Eisai, BMS, Ipsen, and Hengrui; received research funds from MSD, Eisai, Ipsen, SIRTEX, and Zailab; and received honoraria from AstraZeneca, Eisai, Roche, Ipsen, and MSD. Chiara Braconi received honoraria as speaker (AstraZeneca, Incyte, and Servier) and consultant (Incyte, Servier, Boehringer Ingelheim, AstraZeneca, Tahio, and Jazz), received research funds (Avacta, Medannex, and Servier), and her spouse is an employee of AstraZeneca. Masafumi Ikeda reports honoraria from AstraZeneca, Chugai Pharma, Eisai, Incyte, Lilly Japan, MSD, Novartis, Ono Pharmaceutical, Takeda, Teijin Pharma, Nihon Servier, and Taiho and research funding from from AstraZeneca, Bayer, Bristol-Myers Squibb, Chiome Bioscience, Chugai, Eisai, Eli Lilly Japan, Delta-Fly Pharma, Invitae, J-Pharma, Merck biopharma, Merus N.V., MSD, Novartis, Nihon Servier, Ono, Syneos Health, and Rakuten Medical. Gerald W. Prager: advisories and\/or speaker fees: Servier, Bayer, Roche Amgen, Merck, MSD, BMS, Sanofi, Lilly, Astra Zeneca, Astellas, Pierre-Fabre, Incyte, Arcus, and CECOG. Fabian Finkelmeier has received travel support from Ipsen, AbbVie, and AstraZeneca and speaker\u2019s fees from AbbVie, MSD, Ipsen, and Astrazeneca. Guido Giordano: consulting fees: AstraZeneca, MSD, Servier, Seagen, Bayer, Amgen, Novartis, Ipsen, and BMS; travel expenses: Astra Zeneca, Servier, Bayer, and Novartis. Anna Diana reports personal fees (as invited speaker or advisory board)\/travel support from Amgen, Eli Lilly, Pfizer, Novartis, Roche, Gentili, Amgen, Daichii-Sankyo, and Gilead, Ipsen. Sara Lonardi reports personal honoraria as invited speaker from Amgen, Astra Zeneca, Bristol-Myers Squibb, Incyte, GSK, Lilly, Merck Serono, MSD, Pierre-Fabre, Roche, and Servier and participation on advisory board for Amgen, Astellas, Astra Zeneca, Bayer, Bristol-Myers Squibb, Daiichi-Sankyo, GSK, Incyte, Lilly, Merck Serono, MSD, Servier, Takeda, Rottapharm, Beigene, Fosun Pharma, and Nimbus Therapeutics. Jeroen Dekervel received consulting fees and\/or speaker honoraria from Amgen, AstraZeneca, Bayer, BMS, Eisai, Need Inc., Ipsen, Lilly, MediMix, Merck, MSD, Novartis, Roche, and Servier. Jorge Adeva received consulting fees from AstraZeneca, Jazz Pharmaceuticals, MSD, Roche, Servier, Taiho Oncology, and Zymeworks; lecture fees from AstraZeneca, Roche, and Servier; and travel expenses from AstraZeneca, Roche, and Servier. Tanios Bekaii-Saab reports research funding (to institution): Agios, Arys, Arcus, Atreca, Boston Biomedical, Bayer, Eisai, Celgene, Lilly, Ipsen, Clovis, Seattle Genetics, Genentech, Novartis, Mirati, Merus, Abgenomics, Incyte, Pfizer, and BMS; consulting (to institution): Servier, Ipsen, Arcus, Pfizer, Seattle Genetics, Bayer, Genentech, Incyte, Eisai, Merus, Merck KGaA, and Merck; consulting (to self): Stemline, AbbVie, Blueprint Medicines, Boehringer Ingelheim, Janssen, Daiichi Sankyo, Natera, Takeda, TreosBio, Celularity, Caladrius Biosciences, Exact Science, Sobi, Beigene, Kanaph, Astra Zeneca, Deciphera, Zai Labs, Exelixis, MJH Life Sciences, Aptitude Health, Illumina, Foundation Medicine and Sanofi, Glaxo SmithKline, Xilio, IDMC\/DSMB: The Valley Hospital, Fibrogen, Suzhou Kintor, Astra Zeneca, Exelixis, Merck\/Eisai, PanCan, and 1Globe; scientific advisory board: Imugene, Immuneering, Xilis, Replimune, Artiva, and Sun Biopharma; royalties: Uptodate; inventions\/patents: WO\/2018\/183488: Human PD1 peptide vaccines and uses thereof\u2014licensed to Imugene and WO\/2019\/055687: Methods and compositions for the treatment of cancer cachexia\u2014licensed to Recursion. Giulia Tesini received honoraria as speaker from AstraZeneca. She is supported by a Short-Term Scientific Mission grant by the Precision-BTC-Network (COST Action 22125). Salvatore Corallo reports consulting fees and\/or speaker honoraria from Amgen, AstraZeneca, Merck Serono, and Daiichi-Sankyo and travel expenses from AstraZeneca, Incyte, MSD, Roche, and Viatris. Nuno Couto: invited speaker: Incyte, Novartis, and Servier and advisory board participation: AstraZeneca and Roche.\u00a0Francesca Salani received support at UNIPI by European Union-NextGenerationEU through the Italian Ministry of University and Research under PNNR - M4C2-I1.3 Project PE_00000019 \"HEAL ITALIA\" CUP I53C22001440006\".Silvia Camera,\u00a0Margherita Rimini, Mara Persano, Mario Domenico Rizzato, Anna Saborowski, Lorenzo Antonuzzo, Federico Rossari, Tomoyuki Satake, Frederik Peeters, , Silvia Bozzarelli, , Jessica Lucchetti, Jin Won Kim, Oluseyi Abidoye, Ilario Giovanni Rapposelli, Chiara Gallio, Stefano Tamberi, Pircher Chiara, Hong Jae Chon, Aitzaz Qaisar, Alessandro Pastorino, Florian Castet, Emiliano Tamburini, Changhoon Yoo, Alessandro Parisi, Mario Scartozzi, Antonio Avallone, Marta Schirripa, Il Hwan Kim, Lukas Perkhofer, Ester Oneda, Monica Verrico, Gian Paolo Spinelli, Nicola Personeni, Ingrid Garajova, Maria Grazia Rodriquenz, Silvana Leo, Cecilia Melo Alvim, Ricardo Roque, Giovanni Farinea, Virginia Genovesi, Antonio De Rosa, Daniele Lavacchi, Federica Lo Prinzi, Laura Passeri,\u00a0Michele Ferrara, Silvia Foti, Monica Niger, Rita Balsano, Giuseppe Tonini, Minsu Kang, Luca Esposito, Chiara Casadio, Vera Himmelsbach, Matteo Landriscina, Selma Ahcene Djaballah, Gianluca Masi, Arndt Vogel, and Caterina Vivaldi declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the ethics committee of each institution involved in the project. Under the condition of retrospective archival tissue collection and patients\u2019 data anonymization, our study was exempted from the acquisition of informed consent from patients by the institutional review board.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Data available on request from the authors.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Conception and design: S. Camera, A. Casadei-Gardini, M. Rimini, L. Rimassa, and L. Fornaro. Acquisition of data (acquired and managed patients): all authors. Analysis and interpretation of data: S. Camera, A. Casadei-Gardini, M. Rimini, L. Rimassa, and L. Fornaro. Writing, review, and\/or revision of the manuscript: S. Camera, A. Casadei-Gardini, M. Rimini, L. Rimassa, and L. Fornaro. Final approval of manuscript: all authors.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}